Chemotherapy and Beyond

Infections in the Era of Old and New Treatments for Hematologic Malignancies

Sarah Atkins, Fiona He

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Treatment options for hematologic malignancies have been rapidly expanding in the past decade, resulting in better survival outcomes for many patients. Infection is an important cause of morbidity and mortality in this patient population. Cytotoxic chemotherapy has well-studied infectious risks related to the degree and duration of myelosuppression. Targeted therapies and immunotherapies have less clearly predictable infectious risk and diverse effects on immune function. This review discusses contemporary management of hematologic malignancies, followed by special discussion of novel agents, including signaling/small molecule inhibitors, monoclonal antibodies, immunomodulators, and immunotherapies, for treatment of hematologic malignancies with focus on infectious risk.

Original languageEnglish (US)
Pages (from-to)289-309
Number of pages21
JournalInfectious disease clinics of North America
Volume33
Issue number2
DOIs
StatePublished - 2019

Fingerprint

Hematologic Neoplasms
Drug Therapy
Immunotherapy
Infection
Immunologic Factors
Therapeutics
Monoclonal Antibodies
Morbidity
Survival
Mortality
Population

Keywords

  • Chemotherapy
  • Infection
  • Malignant hematology
  • Novel agents
  • Targeted therapy

PubMed: MeSH publication types

  • Journal Article
  • Review

Cite this

Chemotherapy and Beyond : Infections in the Era of Old and New Treatments for Hematologic Malignancies. / Atkins, Sarah; He, Fiona.

In: Infectious disease clinics of North America, Vol. 33, No. 2, 2019, p. 289-309.

Research output: Contribution to journalReview article

@article{750376bf3baf4ae18b5e8c725c76dd91,
title = "Chemotherapy and Beyond: Infections in the Era of Old and New Treatments for Hematologic Malignancies",
abstract = "Treatment options for hematologic malignancies have been rapidly expanding in the past decade, resulting in better survival outcomes for many patients. Infection is an important cause of morbidity and mortality in this patient population. Cytotoxic chemotherapy has well-studied infectious risks related to the degree and duration of myelosuppression. Targeted therapies and immunotherapies have less clearly predictable infectious risk and diverse effects on immune function. This review discusses contemporary management of hematologic malignancies, followed by special discussion of novel agents, including signaling/small molecule inhibitors, monoclonal antibodies, immunomodulators, and immunotherapies, for treatment of hematologic malignancies with focus on infectious risk.",
keywords = "Chemotherapy, Infection, Malignant hematology, Novel agents, Targeted therapy",
author = "Sarah Atkins and Fiona He",
year = "2019",
doi = "10.1016/j.idc.2019.01.001",
language = "English (US)",
volume = "33",
pages = "289--309",
journal = "Infectious Disease Clinics of North America",
issn = "0891-5520",
publisher = "W.B. Saunders Ltd",
number = "2",

}

TY - JOUR

T1 - Chemotherapy and Beyond

T2 - Infections in the Era of Old and New Treatments for Hematologic Malignancies

AU - Atkins, Sarah

AU - He, Fiona

PY - 2019

Y1 - 2019

N2 - Treatment options for hematologic malignancies have been rapidly expanding in the past decade, resulting in better survival outcomes for many patients. Infection is an important cause of morbidity and mortality in this patient population. Cytotoxic chemotherapy has well-studied infectious risks related to the degree and duration of myelosuppression. Targeted therapies and immunotherapies have less clearly predictable infectious risk and diverse effects on immune function. This review discusses contemporary management of hematologic malignancies, followed by special discussion of novel agents, including signaling/small molecule inhibitors, monoclonal antibodies, immunomodulators, and immunotherapies, for treatment of hematologic malignancies with focus on infectious risk.

AB - Treatment options for hematologic malignancies have been rapidly expanding in the past decade, resulting in better survival outcomes for many patients. Infection is an important cause of morbidity and mortality in this patient population. Cytotoxic chemotherapy has well-studied infectious risks related to the degree and duration of myelosuppression. Targeted therapies and immunotherapies have less clearly predictable infectious risk and diverse effects on immune function. This review discusses contemporary management of hematologic malignancies, followed by special discussion of novel agents, including signaling/small molecule inhibitors, monoclonal antibodies, immunomodulators, and immunotherapies, for treatment of hematologic malignancies with focus on infectious risk.

KW - Chemotherapy

KW - Infection

KW - Malignant hematology

KW - Novel agents

KW - Targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=85063517158&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85063517158&partnerID=8YFLogxK

U2 - 10.1016/j.idc.2019.01.001

DO - 10.1016/j.idc.2019.01.001

M3 - Review article

VL - 33

SP - 289

EP - 309

JO - Infectious Disease Clinics of North America

JF - Infectious Disease Clinics of North America

SN - 0891-5520

IS - 2

ER -